Promising Results of First Two Phases of Testing Chinese Coronavirus Vaccine

Source: Slobodna Evropa Monday, 19.10.2020. 13:55
Comments
Podeli
Illustration (Photo: pogonici/shutterstock.com)Illustration
One of China’s front-running coronavirus vaccine candidates was shown to be safe and triggered immune responses in a combined early and mid-stage test in humans, researchers said.

The potential vaccine, dubbed BBIBP-CorV, is being developed by the Beijing Institute of Biological Products, a subsidiary of China National Biotec Group (CNBG), Reuters reports.

It has already been approved for an emergency inoculation program in China targeting essential workers and other limited groups of people facing high infection risk.

However, whether the shot can safely protect people from the COVID-19 disease that has killed more than 1 million people worldwide will only become clear when final Phase III trials - which are ongoing outside China - are complete.

BBIBP-CorV is one of at least 10 coronavirus vaccine projects globally to have entered Phase III trials, four of which are led by Chinese scientists, according to the World Health Organization.

It did not cause any severe side effects, while common mild or moderate adverse reactions included fever and pain in injection sites, according to a paper published on Thursday in medical journal the Lancet. The results came from a combined Phase I and Phase II trial involving more than 600 healthy adults conducted between April 29 and July 30.


Two injections of BBIBP-CorV at three different doses generated antibodies in all recipients of each group, including older participants, although the data does not prove the vaccine is efficacious, researchers at the CNBG subsidiary, Chinese disease control authorities and other research institutes said in the paper.
Comments
Your comment
Full information is available only to commercial users-subscribers and it is necessary to log in.

Forgot your password? Click here HERE

For free test use, click HERE

Follow the news, tenders, grants, legal regulations and reports on our portal.
Registracija na eKapiji vam omogućava pristup potpunim informacijama i dnevnom biltenu
Naš dnevni ekonomski bilten će stizati na vašu mejl adresu krajem svakog radnog dana. Bilteni su personalizovani prema interesovanjima svakog korisnika zasebno, uz konsultacije sa našim ekspertima.